Immunomodulation of selective naive t cell functions by p110δ inactivation improves the outcome of mismatched cell transplantation

Cell Reports

Volumn 10, Issue 5, 2015, Pages 702-710

  Doisne, Jean Marc ^a   Hüber, Christian M ^a   Okkenhaug, Klaus ^b   Colucci, Francesco ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; PROTEIN P110; PROTEIN P110 DELTA; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE; GENE INACTIVATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; P100 DELTA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84923378904     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.01.002     Document Type: Article

References (46)

1. Bian G., Ding X., Leigh N.D., Tang Y., Capitano M.L., Qiu J., McCarthy P.L., Liu H., Cao X. Granzyme B-mediated damage of CD8+ Tcells impairs graft-versus-tumor effect. J.Immunol. 2013, 190:1341-1350.
2. Billottet C., Grandage V.L., Gale R.E., Quattropani A., Rommel C., Vanhaesebroeck B., Khwaja A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006, 25:6648-6659.
3. Chan W.K., Suwannasaen D., Throm R.E., Li Y., Eldridge P.W., Houston J., Gray J.T., Pui C.H., Leung W. Chimeric antigen receptor-redirected CD45RA-negative Tcells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 2014, Published online June 3, 2014. 10.1038/leu.2014.174.
4. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
5. Chen B.J., Deoliveira D., Cui X., Le N.T., Son J., Whitesides J.F., Chao N.J. Inability of memory Tcells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007, 109:3115-3123.
6. Distler E., Bloetz A., Albrecht J., Asdufan S., Hohberger A., Frey M., Schnürer E., Thomas S., Theobald M., Hartwig U.F., Herr W. Alloreactive and leukemia-reactive Tcells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory Tcells. Haematologica 2011, 96:1024-1032.
7. Dutt S., Baker J., Kohrt H.E., Kambham N., Sanyal M., Negrin R.S., Strober S. CD8+CD44(hi) but not CD4+CD44(hi) memory Tcells mediate potent graft antilymphoma activity without GVHD. Blood 2011, 117:3230-3239.
8. Eagle R.A., Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 2007, 7:737-744.
9. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., Negrin R.S. CD4+CD25+ regulatory Tcells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 2003, 9:1144-1150.
10. Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., Barrientos J.C., Zelenetz A.D., Kipps T.J., Flinn I., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N.Engl. J. Med. 2014, 370:997-1007.
11. Garçon F., Patton D.T., Emery J.L., Hirsch E., Rottapel R., Sasaki T., Okkenhaug K. CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood 2008, 111:1464-1471.
12. Ghigo A., Damilano F., Braccini L., Hirsch E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. BioEssays 2010, 32:185-196.
13. Graubert T.A., DiPersio J.F., Russell J.H., Ley T.J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J.Clin. Invest. 1997, 100:904-911.
14. Haarberg K.M., Li J., Heinrichs J., Wang D., Liu C., Bronk C.C., Kaosaard K., Owyang A.M., Holland S., Masuda E., et al. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood 2013, 122:2500-2511.
15. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N.Engl. J. Med. 2013, 369:134-144.
16. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory Tcells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J.Exp. Med. 2002, 196:389-399.
17. Houot R., Kohrt H., Goldstein M.J., Levy R. Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev. 2011, 30:97-109.
18. Hubbard V.M., Eng J.M., Ramirez-Montagut T., Tjoe K.H., Muriglan S.J., Kochman A.A., Terwey T.H., Willis L.M., Schiro R., Heller G., et al. Absence of inducible costimulator on alloreactive Tcells reduces graft versus host disease and induces Th2 deviation. Blood 2005, 106:3285-3292.
19. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16:205-213.
20. Li H.W., Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat. Rev. Immunol. 2012, 12:403-416.
21. Li J., Semple K., Suh W.K., Liu C., Chen F., Blazar B.R., Yu X.Z. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol. Blood Marrow Transplant. 2011, 17:962-969.
22. Li J., Heinrichs J., Leconte J., Haarberg K., Semple K., Liu C., Gigoux M., Kornete M., Piccirillo C.A., Suh W.K., Yu X.Z. Phosphatidylinositol 3-kinase-independent signaling pathways contribute to ICOS-mediated Tcell costimulation in acute graft-versus-host disease in mice. J.Immunol. 2013, 191:200-207.
23. Lutz M.B., Kukutsch N., Ogilvie A.L., Rössner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J.Immunol. Methods 1999, 223:77-92.
24. McDaniel J.M., Pinilla-Ibarz J., Epling-Burnette P.K. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv. Hematol. 2012, 2012:513702.
25. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
26. Ohata J., Sakurai J., Saito K., Tani K., Asano S., Azuma M. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin. Exp. Immunol. 2002, 129:61-68.
27. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 2013, 31:675-704.
28. Okkenhaug K., Bilancio A., Farjot G., Priddle H., Sancho S., Peskett E., Pearce W., Meek S.E., Salpekar A., Waterfield M.D., et al. Impaired B and Tcell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002, 297:1031-1034.
29. Patton D.T., Garçon F., Okkenhaug K. The PI3K p110delta controls T-cell development, differentiation and regulation. Biochem. Soc. Trans. 2007, 35:167-171.
30. Putz E.M., Prchal-Murphy M., Simma O.A., Forster F., Koenig X., Stockinger H., Piekorz R.P., Freissmuth M., Müller M., Sexl V., Zebedin-Brandl E. PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS ONE 2012, 7:e40852.
31. Robb R.J., Lineburg K.E., Kuns R.D., Wilson Y.A., Raffelt N.C., Olver S.D., Varelias A., Alexander K.A., Teal B.E., Sparwasser T., et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory Tcells after experimental allogeneic bone marrow transplantation. Blood 2012, 119:5898-5908.
32. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
33. Sauer M.G., Ericson M.E., Weigel B.J., Herron M.J., Panoskaltsis-Mortari A., Kren B.T., Levine B.L., Serody J.S., June C.H., Taylor P.A., Blazar B.R. A novel system for simultaneous invivo tracking and biological assessment of leukemia cells and exvivo generated leukemia-reactive cytotoxic Tcells. Cancer Res. 2004, 64:3914-3921.
34. Sinclair L.V., Finlay D., Feijoo C., Cornish G.H., Gray A., Ager A., Okkenhaug K., Hagenbeek T.J., Spits H., Cantrell D.A. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 2008, 9:513-521.
35. Soond D.R., Bjørgo E., Moltu K., Dale V.Q., Patton D.T., Torgersen K.M., Galleway F., Twomey B., Clark J., Gaston J.S., et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 2010, 115:2203-2213.
36. Soond D.R., Slack E.C., Garden O.A., Patton D.T., Okkenhaug K. Does the PI3K pathway promote or antagonize regulatory Tcell development and function?. Front. Immunol. 2012, 3:244.
37. Stetson D.B., Mohrs M., Reinhardt R.L., Baron J.L., Wang Z.E., Gapin L., Kronenberg M., Locksley R.M. Constitutive cytokine mRNAs mark natural killer (NK) and NK Tcells poised for rapid effector function. J.Exp. Med. 2003, 198:1069-1076.
38. Sujobert P., Bardet V., Cornillet-Lefebvre P., Hayflick J.S., Prie N., Verdier F., Vanhaesebroeck B., Muller O., Pesce F., Ifrah N., et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106:1063-1066.
39. Taylor P.A., Panoskaltsis-Mortari A., Freeman G.J., Sharpe A.H., Noelle R.J., Rudensky A.Y., Mak T.W., Serody J.S., Blazar B.R. Targeting of inducible costimulator (ICOS) expressed on alloreactive Tcells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 2005, 105:3372-3380.
40. Teschner D., Distler E., Wehler D., Frey M., Marandiuc D., Langeveld K., Theobald M., Thomas S., Herr W. Depletion of naive Tcells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. Bone Marrow Transplant. 2014, 49:138-144.
41. Touzot F., Neven B., Dal-Cortivo L., Gabrion A., Moshous D., Cros G., Chomton M., Luby J.M., Terniaux B., Magalon J., et al. CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study. J.Allergy Clin. Immunol. 2014, 10.1016/j.jaci.2014.08.019.
42. Valenzuela J.O., Iclozan C., Hossain M.S., Prlic M., Hopewell E., Bronk C.C., Wang J., Celis E., Engelman R.W., Blazar B.R., et al. PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J.Clin. Invest. 2009, 119:3774-3786.
43. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N.Engl. J. Med. 2013, 369:122-133.
44. Yang Y., Wang H., Yu H., Yeap B.Y., Liang T., Wang G., Cheng T., Yang Y.G. IFN-γ promotes graft-versus-leukemia effects without directly interacting with leukemia cells in mice after allogeneic hematopoietic cell transplantation. Blood 2011, 118:3721-3724.
45. Zhang Y., Joe G., Hexner E., Zhu J., Emerson S.G. Alloreactive memory Tcells are responsible for the persistence of graft-versus-host disease. J.Immunol. 2005, 174:3051-3058.
46. Zhang Y., Joe G., Hexner E., Zhu J., Emerson S.G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat. Med. 2005, 11:1299-1305.